Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK1557482A is a thimerosal-free formulation of Fluviral, a trivalent inactivated influenza vaccine (TIV) developed by GSK. It is an egg-derived, split-virion vaccine designed to provide active immunization against influenza virus subtypes A and B. This specific formulation was evaluated in pediatric populations (6 months to 3 years of age) to assess safety and immunogenicity at different dose levels (0.25 mL and 0.5 mL) compared to licensed vaccines like Vaxigrip or Fluzone. As a trivalent vaccine, it typically contains antigens from two influenza A strains (H1N1 and H3N2) and one influenza B strain, following WHO recommendations for the relevant season.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fluviral.